dual ATR/HDAC inhibitor (Hangzhou Haolu Pharma/Hangzhou Normal University/University of Burgundy/Shanghai University of Traditional Chinese Medicine)

N/A

Report date: 2025/06/11 10:22:22

NME

Base Information

Drug Namedual ATR/HDAC inhibitor (Hangzhou Haolu Pharma/Hangzhou Normal University/University of Burgundy/Shanghai University of Traditional Chinese Medicine)

Drug Alias NameN/A

ClassificationSmall molecules

Mechanisms of ActionHistone deacetylase 1 inhibitorsHistone deacetylase 6 inhibitorsAnticancer protein kinase inhibitors +[4]

TargetsHistone deacetylase 1Serine-protein kinase ATRHistone deacetylase 6

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFranceMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesHangzhou Normal University

China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Normal University Hangzhou Haolu Pharmaceutical Technology Co., Ltd.University Bourgogne Franche-Comté +[4]

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A